On another front, the Company expects funding to spur progress in the application of Cesium-131 for the treatment of breast cancer. IsoRay recently completed an initial feasibility study which demonstrates the ability to use its patented Cesium-131 internal radiation therapy in accelerated partial breast irradiation (APBI) for breast cancer treatment. APBI is one of the most exciting, emerging treatments available, today, for early stage, localized breast cancer. This new application of Cesium-131 is expected to have a significant impact in the treatment of breast cancer and improve the quality of life for many women who have been diagnosed with the disease.

With established CMS codes, Cesium-131 is FDA-cleared for use in the treatment of cancers throughout the body including breast cancer. More than 100 centers across the country are using Ceium-131 to treat brain, colon, head and neck, lung, ocular melanoma, and prostate cancers.

LifeTech Capital, a Division of Aurora Capital, LLC, acted as the exclusive placement agent in connection with this offering.

SOURCE IsoRay, Inc.